Workshop on Drug Repurposing for Future Pandemics

未来大流行药物再利用研讨会

• 批准号: 2033384
• 负责人: Marinka Zitnik
• 金额: $ 3万
• 依托单位: Harvard University
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-15 至 2020-11-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2033384&HistoricalAwards=false
• 关键词: Workshop; Drug; Repurposing; Future; Pandemics

Developing a drug to treat a new disease, moving the drug forward through clinical trials, and obtaining approval is a long, expensive process with a high risk of failure. An enticing alternative approach to finding a cure for a disease is drug repurposing, which reuses existing drugs, including some that failed in initial trials. Because most repurposed drugs have already passed the early phases of development and clinical testing, they get to market in 6.5 years and cost $300 million on average, less than half the time, and one-quarter of the cost needed to develop a new drug from scratch. While drug repurposing is not new, the speed at which it needs to be implemented during a pandemic is unprecedented. This is the principal open challenge that will be discussed in the workshop. This workshop will provide a forum for researchers who do active and state-of-the-art research in various aspects of drug repurposing. Participants will discuss ways to expedite drug repurposing by compressing years of work into months or even weeks through automation, data science and machine learning, novel data sources, and new biotechnology platforms. The workshop will facilitate community building by bringing together at least two distinct audiences: computational experts who develop algorithms and knowledge experts who use the algorithms as well as other tools for drug repurposing. The workshop results, including the website with linked resources, video recordings, and a perspective paper, will be disseminated broadly via public repositories. The perspective publication will be a roadmap intended for a broad audience with specific recommendations for rapid drug repurposing in future pandemics. Workshop speakers and panelists will be researchers with a wide variety of demographic backgrounds and experiences to promote diversity along several axes (gender, seniority, and affiliation).Historically, successful drug repurposing is based on serendipitous and opportunistic discoveries. However, this approach is unable to produce science-based diagnostic tools at the pandemic scale. This major problem motivates the workshop, which will be held in 2020 as a virtual two-day symposium with open registration and several hundred attendees. The workshop participants will present progress, discuss the challenges of current repurposing research, and recommend innovative ways to address these challenges and realize the full potential of drug repurposing. The workshop will cover topics related to all steps of drug repurposing, including preclinical research, clinical research, regulatory review, and post-market and safety monitoring. Bearing in mind the opportunities and challenges identified at the workshop, the organizers will put forward recommendations on how to compress current repurposing timescales into much shorter ready-to-use solutions to fight emerging pathogens. The organizers anticipate presenting a framework, context, and ultimately guidelines for accelerating the use of data-driven solutions in drug repurposing for the benefit of patients in the US.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

开发治疗新疾病的药物、推动药物通过临床试验并获得批准是一个漫长、昂贵的过程，而且失败的风险很高。寻找疾病治愈方法的一种诱人的替代方法是药物再利用，即重复使用现有药物，包括一些在初步试验中失败的药物。由于大多数再利用药物已经通过了早期开发和临床测试阶段，它们上市需要 6.5 年，平均成本为 3 亿美元，不到开发新药所需时间和成本的一半。划痕。虽然药物重新利用并不新鲜，但在大流行期间实施药物的速度是前所未有的。这是研讨会将讨论的主要公开挑战。该研讨会将为在药物再利用各个方面进行积极和最先进研究的研究人员提供一个论坛。与会者将讨论如何通过自动化、数据科学和机器学习、新颖的数据源和新的生物技术平台将数年的工作压缩为数月甚至数周，从而加快药物的重新利用。该研讨会将通过聚集至少两个不同的受众来促进社区建设：开发算法的计算专家和使用算法以及其他药物重新利用工具的知识专家。研讨会的结果，包括链接资源的网站、视频记录和观点论文，将通过公共存储库广泛传播。该展望出版物将成为面向广大受众的路线图，为未来大流行病中快速重新利用药物提供具体建议。研讨会演讲者和小组成员将是具有各种人口背景和经验的研究人员，以促进多个轴（性别、资历和隶属关系）的多样性。从历史上看，成功的药物重新利用是基于偶然和机会主义的发现。然而，这种方法无法在大流行规模上生产基于科学的诊断工具。这一重大问题激发了研讨会的召开，该研讨会将于 2020 年以虚拟研讨会形式举行，为期两天，开放注册，将有数百名与会者。研讨会参与者将介绍进展情况，讨论当前再利用研究的挑战，并推荐创新方法来应对这些挑战并充分发挥药物再利用的潜力。研讨会将涵盖与药物再利用所有步骤相关的主题，包括临床前研究、临床研究、监管审查以及上市后和安全监测。考虑到研讨会上确定的机遇和挑战，组织者将就如何将当前的重新利用时间表压缩为更短的现成解决方案来对抗新出现的病原体提出建议。组织者预计提出一个框架、背景和最终指南，以加速在药物再利用中使用数据驱动的解决方案，以造福美国患者。该奖项反映了 NSF 的法定使命，并通过使用基金会的智力价值和更广泛的影响审查标准。